Physician profile
Daniel Y Kim
NPI 1477500866
$14,989.21
in general payments reported to CMS, 2019-2025
38 companies · $2,587 in 2025
The $2,587 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,032 · 2020: $1,571 · 2021: $2,090 · 2022: $1,656 · 2023: $2,733 · 2024: $2,322 · 2025: $2,587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,641.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,357.66 | 2022-2025 | |
| Allergan, INC. | $1,234.05 | 2019-2022 | |
| New World Medical,INC. | $1,221.63 | 2023-2024 | Ahmed Glaucoma Valve, Kahook Dual Blade, Clearpath |
| Sun Pharmaceutical Industries INC. | $1,191.14 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $1,165.06 | 2022-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Sight Sciences, INC. | $973.64 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Johnson & Johnson Surgical Vision, INC. | $968.44 | 2019-2025 | Veritas Vision System, Tecnis Simplicity, Tecnis Iol |
| Rxsight INC | $588.95 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Tarsus Pharmaceuticals, INC. | $581.00 | 2024-2025 | Xdemvy |
| Ocular Therapeutix, INC. | $515.15 | 2020-2025 | Dextenza |
| Novartis Pharmaceuticals Corporation | $507.33 | 2019-2022 | |
| Glaukos Corporation | $444.70 | 2024 | Idose Tr, Idose |
| Alcon Vision LLC | $428.73 | 2019-2025 | Rocklatan, Centurion, Acrysof Iq Panoptix Uv Iol |
| Oyster Point Pharma, INC. | $428.49 | 2022-2025 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $377.26 | 2019-2021 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.